The objective of this study was to evaluate the haemodynamic and antiarrhythmic effects of @entity6237 in @entity1 with @entity712 . @entity6237 , a class Ic antiarrhythmic agent, was given intravenously to 9 @entity1 with @entity712 and frequent @entity943 with nonsustained @entity1165 . The drug (2 mg/kg) was infused slowly over 60 minutes. The maximum plasma level achieved was 218 (range 142-350) ng/ml. Six of the 9 @entity1 experienced a 90% suppression of their @entity943 for an average of 6.5 (range 2-15) hours. Pre-ejection period control (PEPc, 148.8 +/- 3.6 msec) increased to 157 msec and pre-ejection period/ejection time (PEP/ET) [control 0.449 +/- 0.027] to 0.516 (p less than 0.005), while the ejection time index (ETI) did not change. Cardiac index (control 2.4 +/- 0.36 L/min/m2) decreased by 11% (p less than 0.02), and pulmonary wedge pressure (control 13.4 +/- 2.4mm Hg) increased by 23% (p less than 0.05). @entity64 work index, arterial pressure and vascular resistance did not change significantly. The parameters returned to control values on completion of the infusion. @entity6237 can be safely administered at the usual dose of 2 mg/kg to @entity1 with @entity712 , provided that the infusion time is doubled. Antiarrhythmic efficacy under these conditions is good even at lower plasma concentrations.

Haemodynamic and antiarrhythmic effects of intravenous @entity6237 in chronic XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure', 'heart failure'] @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia'] @entity64 :: ('MESH:D020521', 'Disease') :: ['Stroke'] @entity6237 :: ('MESH:D005424', 'Chemical') :: ['Flecainide acetate', 'flecainide acetate'] @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmias', 'arrhythmias']
@entity712 :: (MESH:D006333,Disease) :: ['congestive heart failure']
